Transcode Therapeutics Inc.

13F holders, Q1 2025 (March 31)
19holders +14
14new positions
0sold out
$0.49avg. 13F price*

At the end of Q1 2025, 19 institutions reported holding Transcode Therapeutics Inc. in their 13F filings, up 14 from Q4 2024. 14 opened new positions and 0 sold out. The largest holders were Anson Funds Management LP ($724K), UBS Group AG ($131K) and Sabby Management, LLC ($113K).

Company
Transcode Therapeutics Inc.
CUSIP
89357L402
Latest filing quarter
Q1 2025

History

Number of 13F holders

05101520 Q4 2024: 5Q4 2024Q1 2025: 19Q1 2025

Total Exit/New Position Q4 2024 → Q1 2025

InstitutionsTotal Value
New Positions14$926K
Exits0$0

All 13F filers, Q4 2024 → Q1 2025: 2,131,514 shares bought, net +2,131,514 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 19 holders

Anson Funds Management LP 0.18% New 1,462,112 $724K
UBS Group AG 0.00% Add +2942.1% 263,929 $131K
Sabby Management, LLC 0.48% New 229,052 $113K
Warberg Asset Management LLC 0.11% New 50,000 $25K
Corsair Capital Management, L.P. 0.01% New 40,000 $20K
Commonwealth Equity Services, LLC 0.00% New 21,674 $11K
Acadian Asset Management LLC 0.00% New 22,323 $11K
SouthState Bank Corp 0.00% New 18,010 $9K
Ground Swell Capital, LLC 0.02% New 14,363 $7K
Marex Group Ltd 0.00% New 12,678 $6K
Morgan Stanley 0.00% Add +1544.7% 5,000 $2K
Tower Research Capital LLC (TRC) 0.00% Add +64.9% 1,527 $756
SBI Securities Co., Ltd. 0.00% New 374 $185
Osaic Holdings, Inc. 0.00% New 100 $50
FMR LLC 0.00% New 25 $12
Bank of America Corp. 0.00% Add +50.0% 6 $3
Danske Bank A/S 0.00% No change 1 $0
Royal Bank of Canada 0.00% New 250 $0
BlackRock, Inc. 0.00% New 1 $0

"% of holder's portfolio" is TRANSCODE THERAPEUTICS INC's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.